Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HO11415: Bendamustine/Rituximab followed by Rituximab/Lenalidomide in CLL/SLL
NCT01754870Phase 2Withdrawn
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2013
- Primary completion
- Aug 2014
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lenalidomide in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of Wisconsin–Madison. Planned start Nov 2013; status: withdrawn.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01754870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01754870.